Ovarian Cancer — Microbiome Signature

The most lethal gynecological malignancy (~314,000 new cases, ~207,000 deaths annually), with >70% diagnosed at stage III/IV. The microbiome signature of ovarian cancer is distinctive for its multi-compartment oncobiosis — simultaneous dysbiosis across gut, cervicovaginal, peritoneal, and tumor tissue compartments — and for the convergence of metalloestrogen biology, ferroptosis resistance, and ascending infection pathways. The microbiome is not merely associated with ovarian cancer; it is functionally required for immune surveillance of cancer stem cells and for the efficacy of chemotherapy.

Metallomic Signature

Confidence: moderate — strong mechanistic evidence from entity page and epidemiological associations, but limited direct tissue quantification in the ingested source corpus.

  • cadmium elevated: Primary metalloestrogen. Binds ERalpha with Kd ~4.5 x 10^-10 M (nearly equivalent to estradiol). Activates ER-dependent transcription in OC cells at 1 uM. Also signals through GPR30/GPER in ER-negative cells at 50-500 nM. Half-life 12-30 years, creating cumulative ovarian tissue burden. Smoking is primary non-occupational exposure source.
  • nickel elevated: Binds ERalpha noncompetitively; drives epigenetic changes (global loss of histone acetylation, H3K9 methylation) that may promote carcinogenesis independently of estrogenic effects.
  • arsenic elevated: Associated with increased OC risk through oxidative stress, DNA damage, and interference with DNA repair pathways.
  • iron elevated in tumor microenvironment: OC cells upregulate transferrin receptor 1 (TfR1) and downregulate ferroportin, creating an iron-accumulating phenotype. Endometriosis-associated subtypes (clear cell, endometrioid) develop in iron-rich environment from retrograde menstruation. Iron drives Fenton chemistry generating ROS.
  • Glutathione depleted/dysregulated: Central to platinum resistance. Glutathione synthesis is the most significantly altered pathway in platinum-resistant OC [1]. Platinum-resistant cells upregulate glutathione, resisting ferroptosis.
  • Taurine depleted: Antioxidant defense compromised in OC tissue [2].

Environmental Exposures

SourceMetalsRelevance
SmokingCadmium (primary)35-50% higher Cd body burden in smokers
DietCd, As, NiContaminated soils, rice, shellfish, leafy greens
OccupationalCd, Ni, AsBattery production, smelting, electronics
EndometriosisIronRepeated retrograde menstruation deposits iron in peritoneal/ovarian tissue (RR 1.265 for OC, [3])

Nutritional Immunity Response

Confidence: preliminary — scattered immune data, no systematic nutritional immunity profiling in current sources.

MarkerDirectionEvidence
Tumor-associated macrophagesElevatedInfiltrate inflammatory tumor microenvironment [4]
Inflammatory cytokinesElevated; mediate gut-OC axisGenetically predicted causal mediation [5]
LPSPresent in tumor tissueConfirmed by immunohistochemistry [6]
B-cell/IgA responseSuppressed by TRAF3Intact microbiome required for B-cell antitumor immunity; TRAF3 knockout restores MHC-I and type-I IFN [7]
Indole-3-propionic acidDepleted by antibioticsProtective metabolite suppressed by dysbiosis; restored by FMT [8]
Omega-oxidation enzymesSuppressedPPARalpha, CYP4F3, CYP4A10 downregulated; restored by probiotics [9]
GlutathioneDepleted in sensitive tumors / elevated in resistantCentral to ferroptosis resistance [1]

Mis-metallation Events

  • Cadmium as molecular mimic of estradiol: Cd displaces natural estrogen signaling at ERalpha, driving proliferative responses in ovarian epithelial cells. Co-exposure with nickel may produce synergistic carcinogenic effects through converging estrogenic and epigenetic mechanisms.
  • Iron accumulation and ferroptosis resistance: Iron-accumulating OC cells should be vulnerable to ferroptosis, but platinum-resistant cells upregulate the Keap1-Nrf2-GPX4 axis to resist iron-dependent cell death. This creates a paradox: iron feeds tumor growth AND could be the mechanism for tumor killing if ferroptosis resistance is overcome.

Taxonomic Analysis

Confidence: moderate — multiple studies across compartments, with MR causal evidence supplementing observational data.

Multi-Compartment Oncobiosis

Ovarian cancer is unique in that dysbiosis occurs simultaneously across multiple body compartments:

Tumor Tissue:

TaxonDirectionEvidence
Proteobacteria (phylum)EnrichedProteobacteria/Firmicutes ratio increased ([10], n=137)
Propionibacterium acnesEnrichedInflammatory potential [4]
Firmicutes (phylum)DepletedRelative decrease [10]
Crenarchaeota (archaea)DepletedArchaeal diversity reduced [6]

Gut:

TaxonDirectionEvidence
Escherichia-ShigellaEnrichedMarkedly higher in OC ([11], n=382)
DialisterEnriched (causal)Two independent MR studies ([12], [13])
CoprococcusDepletedButyrate producer [11]
FusicatenibacterDepletedSCFA producer [11]
ButyricicoccusDepletedSCFA producer [11]
OscillibacterDepletedSCFA producer [11]
Bifidobacterium bifidumProtective (causal)MR evidence [12]

Cervicovaginal:

TaxonDirectionEvidence
Lactobacillus dominanceLostNon-Lactobacillus community type O: OR 2.80 for OC in women <50 ([14], Lancet Oncology, n=580)

Peritoneal: 18 microbial features specific to OC pathology identified; combined with CA-125 and HE4, improved diagnostic accuracy [15].

Virulence Enzymes and Features

Confidence: preliminary — functional predictions from metagenomics, limited direct enzyme measurement.

  • LPS biosynthesis: Gram-negative enrichment confirmed across compartments; LPS detected in tumor tissue by immunohistochemistry
  • Beta-glucuronidase (estrobolome): Estrogen deconjugation by gut bacteria implied by estrogen-dependent OC biology; not directly measured in current sources
  • Oxidative stress tolerance enzymes: Enriched in tumor tissue bacteria (KEGG pathway analysis, [6])
  • Keap1-Nrf2-GPX4 axis: Ferroptosis resistance pathway upregulated in platinum-resistant OC; targetable by Tripterygium + Lactobacillus [16]
  • Siderophore systems: Consistent with Escherichia-Shigella enrichment and iron-scavenging competitive advantage

Interkingdom Relationships

  • Mycobiome: Candida and Malassezia species identified in ovarian tumor tissue. Fungal beta-glucans activate complement and modulate antitumor immunity through Dectin-1 receptor signaling.
  • Ascending infection model: Vaginal pathogens (Neisseria gonorrhoeae, Chlamydia trachomatis) increase OC risk. Lactobacillus depletion in cervicovaginal compartment enables pathogen ascension to upper reproductive tract. Tubal ligation disrupts this pathway [17].
  • IgA-coated bacteria in ascites: Unique microbial-immune interaction at the tumor site; commensal microbiota required for B-cell-mediated antitumor immunity [7].

Ecological State

Confidence: moderate — consistent patterns across multiple studies.

1. Multi-Compartment Oncobiosis

Simultaneous dysbiosis across gut, cervicovaginal, peritoneal, and tumor tissue. Shannon index significantly decreased in OC tumor tissue (P=0.0215, [10]). Gut-based random forest classifier achieves AUC = 0.86 for OC detection [11].

2. SCFA Depletion

Systematic loss of butyrate-producing genera (Coprococcus, Fusicatenibacter, Butyricicoccus, Oscillibacter) in gut. Butyric acid metabolites identified as protective factors by Mendelian randomization [12].

3. Ferroptosis Resistance

Platinum-resistant OC cells upregulate glutathione synthesis and the Keap1-Nrf2-GPX4 axis, resisting iron-dependent cell death. This is the primary chemoresistance mechanism and a key therapeutic target.

4. Microbiome-Dependent Chemotherapy Efficacy

Antibiotic-induced dysbiosis increases tumor growth AND cisplatin resistance. Gut microbiome is required for immune surveillance of cancer stem cells. IPA and indoxyl sulfate are key protective metabolites suppressed by antibiotics, restored by FMT [8].

5. Metabolic Reprogramming

Warburg-like shift in OC tissue: carnitine elevated 1.75-fold, butyrylcarnitine 3.62-fold, taurine depleted [2]. Stage IV OC ascites metabolome converges with GI cancers, suggesting gut barrier breakdown in advanced disease [18].

6. Diet-Microbiome-Cancer Axis

High-fat and ketogenic diets accelerate EOC tumor growth via microbiome disruption and polyamine biosynthesis upregulation [19]. Mediterranean diet shows survival benefit (HR=0.59, [20]).

Associated Conditions

ConditionShared MetalsShared TaxaShared EcologyOverlap Score
endometriosisIron, Cd, NiE. coli, F. nucleatumEstrogen recirculation, iron accumulation, biofilm0.65
breast cancerCd, Fe, NiE. coli, F. nucleatumMetalloestrogen signaling, estrobolome dysfunction0.60
colorectal cancerFe, CdF. nucleatum, B. fragilisSCFA depletion, inflammation-driven carcinogenesis0.55
pancreatic cancerCd, NiProteobacteria enrichedInflammation-driven, ferroptosis resistance0.40

Endometriosis is a direct risk factor for OC (RR 1.265, [3]), with iron deposits from retrograde menstruation contributing to carcinogenesis in clear cell and endometrioid subtypes.

Validated Interventions

InterventionClassEvidenceKey OutcomePage
Dietary fiberDietarySR/MA, 13 studies, n=142,189RR 0.78; 12% risk reduction per 10g/daydietary fiber ovarian cancer
Mediterranean dietDietaryProspective cohortHR 0.59 for overall survivalmediterranean diet ovarian cancer
Indole-3-carbinolSupplementIn vitro + animal model (3 papers)EGFR inhibition, bortezomib sensitization, cisplatin chemoprotectionindole 3 carbinol ovarian cancer

Promising:

  • Tripterygium glycosides + L. paracasei — induces ferroptosis via GPX4 inhibition, microbiome-dependent ([16], animal model)
  • Post-surgical probiotics — restores diversity, activates omega-oxidation [9]
  • E. coli Nissle 1917 — reduces tumor via TLR-4/IL-23, but only in unstressed mice [21]

STOPs

STOPRationalePage
Broad-spectrum antibiotics during chemotherapyABX disrupts protective microbiome, increases tumor growth and cisplatin resistance, suppresses IPA/indoxyl sulfate, enriches cancer stem cellsstop antibiotics during chemotherapy ovarian cancer
Probiotics without stress managementChronic stress/cortisol overrides probiotic immune modulation; EcN failed in stressed micestop probiotics without stress management ovarian cancer

Open Questions

  1. Direct metallomic quantification: No study in our corpus directly measures Cd, Ni, As tissue concentrations alongside microbiome profiling in the same OC cohort. This would cement Layer 1.
  2. Ferroptosis induction in clinical trials: Can the Tripterygium + Lactobacillus approach overcome platinum resistance in humans?
  3. Cervicovaginal screening: Can non-Lactobacillus community state type serve as early OC biomarker, especially in BRCA carriers?
  4. Peritoneal microbiome specifics: Miao 2020 identified 18 OC-specific features — full characterization needed.
  5. Estrobolome quantification: Beta-glucuronidase activity in OC patient gut microbiome has not been directly measured.
  6. Stress-probiotic interaction: Can HPA axis interventions (cortisol management) rescue probiotic efficacy in OC patients?

Knowledge Primitives Applied

  • 1. Metals as Selective Pressures — Cadmium, nickel, arsenic select for metal-tolerant pathobionts in tumor microenvironment
  • 2. Nutritional Immunity as Interpretive Constraint — TRAF3-mediated immune suppression overrides B-cell antitumor response
  • 3. Mis-metallation and Toxic Metal Entry — Cadmium mimics estradiol at ERalpha; nickel drives epigenetic carcinogenesis
  • 4. Microbial Metal Dependencies as Achilles' Heels — Iron-dependent ferroptosis as therapeutic strategy; restrict GPX4 to sensitize tumors
  • 5. Two-Sided Ecological Engineering — Suppress pathobionts AND restore butyrate producers; antibiotics do the opposite
  • 6. Interkingdom Relationships and Functional Shielding — Fungal-bacterial interactions in tumor microenvironment; Candida/Malassezia in tumor tissue
  • 7. Estrobolome and Hormone Recirculation — Beta-glucuronidase-mediated estrogen recirculation feeds estrogen-dependent OC
  • 8. Siderophore Competition and Iron Ecology — Escherichia-Shigella enrichment consistent with iron-scavenging competitive advantage

References (31)

  1. Lori M. Poisson, Adnan Munkarah, Hala Madi et al. (2015). Poisson 2015 — A Metabolomic Approach to Identifying Platinum Resistance in Ovarian Cancer. Journal of Ovarian Research. doi:10.1186/s13048-015-0140-8
  2. Fong MY, McDunn J, Kakar SS (2011). Fong 2011 — Identification of Metabolites in the Normal Ovary and Their Transformation in Primary and Metastatic Ovarian Cancer. PLoS ONE. doi:10.1371/journal.pone.0019963
  3. Kim HS, Kim TH, Chung HH et al. (2014). Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. British Journal of Cancer. doi:10.1038/bjc.2014.29
  4. Min Zhang, Jiao Mo, Wei Huang et al. (2024). Zhang 2024 — The Ovarian Cancer-Associated Microbiome Contributes to the Tumor's Inflammatory Microenvironment. Frontiers in Cellular and Infection Microbiology. doi:10.3389/fcimb.2024.1440742
  5. Li Chuan, Bingke Yao, Hui Zhang et al. (2026). Chuan 2026 — Genetically Predicted Inflammatory Cytokines Mediate the Associations Between the Gut Microbiota and Ovarian Cancer. Journal of Ovarian Research. doi:10.1186/s13048-026-01963-9
  6. Wang Q, Zhao L, Han L et al. (2020). The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ. Journal of Ovarian Research. doi:10.1186/s13048-019-0603-4
  7. Jonathan Zorea, Yair Motro, Rami D. Mazor et al. (2023). Zorea 2023 — TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer. Journal of Experimental and Clinical Cancer Research. doi:10.1186/s13046-023-02680-7
  8. Hawkins SM, Nephew KP (2022). Hawkins 2022 — Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer. Cancer Research. doi:10.1158/0008-5472.CAN-22-3013
  9. Chao Geng, Qi Cao, Zhiyu Chen et al. (2026). Geng 2026 — The Protective Effect of Probiotic Therapy on Gut Microbiota and the Activation of Omega-Oxidation After Ovarian Cancer Surgery. Journal of Cancer Research and Clinical Oncology. doi:10.1007/s00432-025-06398-1
  10. Zhou B, Sun C, Huang J et al. (2019). The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients. Scientific Reports. doi:10.1038/s41598-018-38031-2
  11. Gong W, Jin G, Bao Y et al. (2025). Characteristics and potential diagnostic value of gut microbiota in ovarian tumor patients. Scientific Reports. doi:10.1038/s41598-025-99912-x
  12. Jia Guo, Cheng Wang, Hui Li et al. (2025). Guo 2025 — Exploring the Causal Associations of the Gut Microbiota and Plasma Metabolites with Ovarian Cancer. Journal of Ovarian Research. doi:10.1186/s13048-025-01610-9
  13. Li Zhang, Ting Cao, Kunhong Liu et al. (2024). Zhang 2024 — Genetically Predicted Blood Metabolites Mediate Relationships Between Gut Microbiota and Ovarian Cancer. Frontiers in Cellular and Infection Microbiology. doi:10.3389/fcimb.2024.1451880
  14. Nene NR, Reisel D, Leimbach A et al. (2019). Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. The Lancet Oncology
  15. Miao R, Badger TC, Groesch K et al. (2020). Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer. PLoS ONE. doi:10.1371/journal.pone.0227707
  16. Tian M, Zeng X, Zhong Y et al. (2026). Tian et al. 2026 — Tripterygium Glycosides and Lactobacillus paracasei Sensitize EOC to Cisplatin via Keap1-Nrf2-GPX4 Pathway. Cellular and Molecular Biology Letters. doi:10.1186/s11658-025-00850-3
  17. Qin X, Zhou J, Wang Z et al. (2022). Qin 2022 — Metagenomic Analysis of Upper Reproductive Tract Microbiome in Ovarian Cancer. EPMA Journal. doi:10.1007/s13167-022-00286-1
  18. Shutian Deng, Woojin Kim, Kai Cheng et al. (2025). Deng 2025 — Identification and Impact of Microbiota-Derived Metabolites in Ascites of Ovarian and Gastrointestinal Cancer. Cancer and Metabolism. doi:10.1186/s40170-025-00391-5
  19. AlHilli MM, Sangwan N, Myers A et al. (2025). The effects of dietary fat on gut microbial composition and function in a mouse model of ovarian cancer. Journal of Ovarian Research. doi:10.1186/s13048-025-01731-1
  20. Chen YH, Bao RH, Liu JC et al. (2024). Association between pre-diagnosis and post-diagnosis Alternate Mediterranean Diet and ovarian cancer survival. Journal of Translational Medicine. doi:10.1186/s12967-024-05653-2
  21. Al-Natsheh M (2022). Al-Natsheh 2022 — Stress and Probiotics in Ovarian Cancer. University of Brighton PhD Thesis
  22. Sipos A, Ujlaki G, Miko E et al. (2021). The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Molecular Medicine. doi:10.1186/s10020-021-00295-2
  23. Lee SR, Lee JC, Kim SH et al. (2021). Altered Composition of Microbiota in Women with Ovarian Endometrioma: Microbiome Analyses of Extracellular Vesicles in the Peritoneal Fluid. International Journal of Molecular Sciences. doi:10.3390/ijms22094608
  24. Englert-Golon M, Sajdak S, Plagens-Rotman KM et al. (2025). Englert-Golon 2025 — Potential Role of Microbiota in Ovarian Cancer Treatment. Archives of Medical Science. doi:10.5114/aoms/209544
  25. Montoya VK (2013). Metagenomic Analyses of Two Female Genital Tract Diseases: Bacterial Vaginosis and Ovarian Cancer. University of British Columbia MSc Thesis
  26. Dash R, Hosen SMZ, Karim MR et al. (2015). In silico analysis of indole-3-carbinol and its metabolite DIM as EGFR tyrosine kinase inhibitors in platinum resistant ovarian cancer. Journal of Applied Pharmaceutical Science. doi:10.7324/JAPS.2015.501112
  27. Taylor-Harding B, Agadjanian H, Nassanian H et al. (2012). Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. British Journal of Cancer. doi:10.1038/bjc.2011.546
  28. Bin Zheng, Hong Shen, Huan Han et al. (2018). Zheng 2018 — Dietary Fiber Intake and Reduced Risk of Ovarian Cancer: A Meta-Analysis. Nutrition Journal. doi:10.1186/s12937-018-0407-1
  29. Zhu F, Li F, Zhang R et al. (2026). Indole-3-carbinol alleviates cisplatin-induced ovarian damage by inhibiting ovarian fibrosis through the TGF-beta1/Smad pathway. Journal of Ovarian Research. doi:10.1186/s13048-026-01994-2
  30. Reid BM, Permuth JB, Sellers TA (2017). Reid 2017 — Epidemiology of Ovarian Cancer: A Review. Cancer Biology and Medicine. doi:10.20892/j.issn.2095-3941.2016.0084
  31. Yammine SG, Huybrechts I, Biessy C et al. (2020). Dietary and circulating fatty acids and ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention